LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Search

Pacific Biosciences of California Inc

Fechado

SetorSaúde

1.57 -7.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.51

Máximo

1.7

Indicadores-chave

By Trading Economics

Rendimento

3.9M

-38M

Vendas

6.2M

45M

Margem de lucro

-98.853

Funcionários

575

EBITDA

-8.8M

-41M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+46.2% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-39M

516M

Abertura anterior

9.22

Fecho anterior

1.57

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Pacific Biosciences of California Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de fev. de 2026, 23:44 UTC

Ações em Alta

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 de fev. de 2026, 23:20 UTC

Ganhos

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 de fev. de 2026, 22:57 UTC

Ganhos

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 de fev. de 2026, 21:59 UTC

Ganhos

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

17 de fev. de 2026, 23:54 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de fev. de 2026, 23:45 UTC

Conversa de Mercado

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 de fev. de 2026, 23:19 UTC

Ganhos

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 de fev. de 2026, 23:15 UTC

Ganhos

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 de fev. de 2026, 22:58 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 de fev. de 2026, 22:58 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 de fev. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 de fev. de 2026, 22:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 de fev. de 2026, 22:44 UTC

Ganhos

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 de fev. de 2026, 22:42 UTC

Ganhos

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 de fev. de 2026, 22:36 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 de fev. de 2026, 22:36 UTC

Ganhos

Santos Final Dividend 10.3 U.S. Cents/Security

17 de fev. de 2026, 22:36 UTC

Ganhos

Santos FY Underlying Profit US$898 Million, Down 25%

17 de fev. de 2026, 22:35 UTC

Ganhos

Santos FY Revenue US$4.94 Billion, Down 8%

17 de fev. de 2026, 22:35 UTC

Ganhos

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 de fev. de 2026, 22:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 de fev. de 2026, 22:34 UTC

Ganhos

Santos FY Net Profit US$818 Billion, Down 33%

17 de fev. de 2026, 22:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 de fev. de 2026, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 de fev. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

17 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de fev. de 2026, 21:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 de fev. de 2026, 21:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 de fev. de 2026, 21:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Comparação entre Pares

Variação de preço

Pacific Biosciences of California Inc Previsão

Preço-alvo

By TipRanks

46.2% parte superior

Previsão para 12 meses

Média 2.5 USD  46.2%

Máximo 3 USD

Mínimo 2 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

2

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.13 / N/ASuporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat